Warner-lambert Company

Amgen Fremont Inc.

Abgenix, Inc.

James Leslie Mobley

Ian Nevin Foltz

Mary Haak-Frendscho

Vahe Bedian

Joseph Edwin Low

Madhav Narasimha Devalaraja

Sirid-Aimee Kellermann

Sirid-Aimée Kellermann

Alexander James Bridges

Alan Robert Saltiel

David Thomas Dudley

The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to a M-CSF, preferably human M-CSF, and that function to inhibit a M-CSF. The invention also relates to human anti-M-CSF antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-M-CSF antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-M-CSF antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-M-CSF antibodies. The invention also relates to transgenic animals and transgenic plants comprising nucleic acid molecules of the present invention.

Antibodies to M-CSF

Nucleic acid molecules encoding antibodies to M-CSF

Methods of treating arthritic conditions with antibodies to M-CSF

This invention provides a method of preventing or treating asthma by administering to a patient in need of treatment an effective amount of a selective MEK inhibitor, especially a phenyl amine of Formula I and II:

Treatment of asthma with MEK inhibitors

Growing community of inventors

Brighton, MI, United States of America

James Leslie Mobley